Patients diagnosed with a transient ischemic attack (TIA) or ischemic stroke undergo extensive testing to identify a cause for the purpose of optimal secondary stroke prevention. In individuals under age 50 without other risk factors, this work up includes screening for inherited and acquired hypercoagulable disorders (Case).
It is important to keep in mind that finding a coagulation disorder in a person with brain ischemia may be coincidental, not causal,1 especially if there is evidence for other possible causes of ischemia.2 It can also be difficult to test for hypercoagulation disorders in the acute setting.
There are other diagnostic tests to consider in this population. If there is clinical suspicion based on history and examination, or if infarcts appear embolic and span multiple vascular territories, and the individual has an intracardiac shunt, peripheral venous duplex ultrasound is recommended. If infarcts appear embolic in the setting of known or suspected valve disease, including endocarditis or hypercoagulability a transesophageal echocardiogram (TEE) should be considered because it offers a better view of posterior cardiac structures. Cardiac CT is noninvasive and can offer comparable diagnostic information as TEE, depending on the indication.
Hypercoagulability describes a prothrombotic state that confers a predisposition to thrombus formation in arteries and veins. Hypercoagulability disorders may be inherited or acquired.
Inherited Coagulation Disorders
Factor V Leiden (FVL) mutations are the most common inherited hypercoagulable disorder, followed by prothrombin 20210A (PTG) mutation. Others include deficiencies in protein S, protein C, antithrombin, or methylenetetrahydrofolate reductase (MTHFR) mutations associated with hyperhomocysteinemia.3 Antiphospholipid syndrome (APS), an acquired systemic autoimmune disorder will be discussed briefly, but other acquired coagulation disorders and less common disorders such as elevated factor VIII and fibrinogen defects are outside the scope of this article.
Factor V Leiden Mutation. Mutation of FVL at an arginine cleavage site results in protein C that, when activated, does not break down the procoagulant Factor V, causing a hypercoagulable state. The FVL mutation is associated with VTE including cerebral venous sinus thrombosis (CVST).4,5 An association of FVL mutations with arterial thrombosis (eg, myocardial infarction or ischemic stroke) is proposed but controversial6 and likely small if present. Genetic testing for FVL mutations is highly accurate in the inpatient setting. Functional activated protein C (aPC) assays, which may rely on activated partial thromboplastin time (aPTT), however, can be affected by use of direct thrombin inhibitors, factor Xa inhibitors, coexisting lupus anticoagulant (LAC), or other anticoagulants.7
Prothrombin G20210A Mutation. A gain-of-function point mutation in the prothrombin gene causes elevated plasma levels of prothrombin, a precursor for thrombin, resulting in a hypercoagulable state. Although the PTG mutation is an established risk factor for VTE, including CVST,4 its link for arterial and intramural thrombotic disease is less clear,8 especially in the absence of a persistent foramen ovale (PFO). Meta-analyses of case control and/or cohort studies show an association between PTG mutation and increased ischemic stroke risk, especially in children9; however, other high-quality studies refute that association.10,11 Homozygous PTG mutations are less common, result in even higher PT levels, and carry a higher risk of VTE. The presence of both FVL and PTG mutations or use of oral contraceptives can increase VTE risk, including risk of CVST.5 Genetic testing for PTG mutations is performed with PCR or DNA microarray technology3 and is unaltered in the inpatient setting.
Protein C, Protein S, and Antithrombin Deficiencies. Once activated by thrombin, protein C proteolytically degrades procoagulant factors Va and VIIIa, using Protein S as a cofactor.3 Antithrombin inactivates activated thrombin and to a lesser extent, factors IXa, XIa, and XIIa. Thus, a deficiency in these proteins, hereditary or acquired, can result in a hypercoagulable state. Antithrombin, and to a lesser extent, protein C and S deficiencies have been associated with VTE; association with arterial phenomena such as ischemic stroke has not been extensively studied. Small case reports have suggested an association with stroke, but this was not shown in a larger case-control study and there are conflicting results in other prospective studies.1,12,13 Functional assays are used as screening tests, followed by immunologic/antigenic assays if results are abnormal.3 Functional assays, especially when clot based, can be falsely increased by anticoagulants or coexisting LAC or FVL mutations and falsely decreased by elevated factor VIII levels, acute phase reactants, thrombosis, surgery, and liver disease. Low protein S levels can falsely decrease aPC assay results.3 Antigenic assays lack specificity and can be affected by FVL mutation and LACs.3 Because of multiple interactions, inpatient testing is not recommended.
Methylenetetrahydrofolate Reductase Mutation Associated With Hyperhomocysteinemia. Homocysteine is an amino acid that is metabolized to methionine by MTHFR or to cystathionine. Metabolism of homocysteine requires vitamin B12, folate, and vitamin B6 as cofactors. Genetic polymorphisms of the enzymes in these metabolic pathways can cause hyperhomocysteinemia, which has been associated with stroke and cerebrovascular disease.14 Diagnosis of MTHFR hyperhomocysteinemia is made by genetic testing and not affected in the acute setting. It is important to note, however, that although clinical trials have shown safe and effective reduction of homocysteine levels with vitamin supplementation, reduction of stroke risk has not been seen.15
The most common acquired hemophilia, APS is a systemic autoimmune disorder characterized by VTE, arterial thrombosis including ischemic stroke, and/or specific pregnancy complications in the presence of antiphospholipid antibodies (aPL).3 Autoimmune diseases (eg, systemic lupus erythematosus) may cause APS, but it can also occur alone. Antibodies to aPL are directed against phospholipid protein complexes. Clinical and laboratory criteria must be met for APS diagnosis. Laboratory testing includes LAC, IgG, and IgM subclasses of anticardiolipin (aCL) and antiβ2-glycoprotein (GP) antibodies on 2 occasions at least 12 weeks apart. Data to demonstrate definite causality is conflicting, but overwhelming evidence suggests there is an association between aPL antibodies and ischemic stroke in young adults.15
Inpatient laboratory testing is not recommended because it can be confounded by a variety of clinical conditions including acute phase response, thrombosis, drug interactions, and infections.3 Anticoagulants may affect LAC but not aCL or GP antibody testing.
In the setting of thrombotic disorders, acute VTE including stroke due to CVST, should be managed according to guidelines using systemic anticoagulation for at least 3 to 6 months. Prophylactic therapy should be considered during periods of heightened coagulopathy risk (eg, pregnancy, postpartum, and postoperatively). Antiplatelet therapy or moderate-intensity anticoagulation is recommended for individuals with an inherited hypercoagulable disorder and ischemic stroke, but evidence to support this approach is limited to small studies with methodological shortcomings.2 Guidelines recommend antiplatelet therapy for people with aPL who do not meet criteria for APS and consideration of anticoagulant therapy for those with APS and stroke.15 In addition, the guidelines state anticoagulation may be reasonable for individuals with an inherited hypercoagulable disorder who have recurrent ischemic stroke of unexplained etiology. Current recommendations in adults with hyperhomocysteinemia associated with a genetic mutation are supplementation with folate, vitamins B6, and B12 because it is safe even if it may not reduce stroke risk.15
Hereditary hypercoagulable disorders are rare. Despite association of some conditions with ischemic arterial stroke, evidence for causality remains controversial. Screening for prothrombotic conditions is recommended in several current guidelines and is often part of the diagnostic workup for people experiencing ischemic stroke.2 The yield of testing for these disorders is limited in the inpatient setting and may only be useful in some people with acute stroke.
Antiplatelet or anticoagulation therapy may be reasonable in people with ischemic stroke and an inherited thrombotic disorder. Prospective data are needed to further understand the role of coagulation disorders in the pathogenesis of ischemic stroke, the utility of testing for these disorders, and the optimal management of people with inherited hypercoagulable disorders who have a stroke.
1. Hankey GJ, Eikelboom JW, van Bockxmeer FM, Lofthouse E, Staples N, Baker RI. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke. 2001;32(8):1793-1799.
2. de Lau LM, Leebeek FW, de Maat MP, Koudstaal PJ, Dippel DW. Screening for coagulation disorders in patients with ischemic stroke. Expert Rev Neurother. 2010;10(8):1321-1329.
3. Nakashima MO, Rogers HJ. Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants. Blood Res. 2014;49(2):85-94.
4. Simone B, De Stefano V, Leoncini E, et al. Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, prothrombin 20210A and methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol. 2013;28(8):621-647.
5. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. New Engl J Med. 1998;338(25):1793-1797.
6. Lalouschek W, Schillinger M, Hsieh K, et al. Matched case-control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years. Stroke. 2005;36(7):1405-1409.
7. Kadauke S, Khor B, Van Cott EM. Activated protein C resistance testing for factor V Leiden. Am J Hematol. 2014;89(12):1147-1150.
8. Saadatnia M, Salehi M, Amini G, Seyyed Agha Miri N. The impact of prothrombin (G20210A) gene mutation on stroke in youths. Arya Atheroscler. 2012;8(1):9-11.
9. Sarecka-Hujar B, Kopyta I, Skrzypek M, Sordyl J. Association between the 20210G: a prothrombin gene polymorphism and arterial ischemic stroke in children and young adults-two meta-analyses of 3586 cases and 6440 control subjects in total. Pediatr Neurol. 2017;69:93-101.
10. Coppens M, van de Poel MH, Bank I, et al. A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. Blood. 2006;108(8):2604-2607.
11. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation. 1999;99(8):999-1004.
12. Kohler J, Kasper J, Witt I, von Reutern GM. Ischemic stroke due to protein C deficiency. Stroke. 1990;21(7):1077-1080.
13. Strater R, Becker S, von Eckardstein A, et al. Prospective assessment of risk factors for recurrent stroke during childhood--a 5-year follow-up study. Lancet. 2002;360(9345):1540-1545.
14. Moller J, Nielsen GM, Tvedegaard KC, Andersen NT, Jorgensen PE. A meta-analysis of cerebrovascular disease and hyperhomocysteinaemia. Scand J Clin Lab Invest. 2000;60(6):491-9.
15. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2014;45(7):2160-2236.
SR reports no disclosures.